Bionature focuses on the development of novel, proprietary, blood-brain barrier permeable small molecules for the treatment of neuroinflammatory and neurodegenerative diseases, such as diabetic retinopathy, demyelination and multiple sclerosis, Parkinson and Alzheimer diseases. Bionature’s team has discovered that its synthetic small molecules interact with the receptors of the endogenous neurotrophins, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and are therefore referred to as “microneurotrophins.”
Microneurotrophins have been shown to be very effective in preventing and reversing the demyelination and neuronal degeneration observed in the cuprizone mouse model of demyelination and multiple sclerosis (MS) and in preventing apoptosis in animal models of diabetic retinal degeneration, Alzheimer and Parkinson diseases. They are also strong inducers of neurogenesis ex vivo and in vivo, propagating the formation of fresh neural tissue.
Για περισσότερες πληροφορίες επισκεφτείτε την ιστοσελίδα https://www.bionature.net
